- Benzinga
Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal
Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl
